General Information of Drug (ID: DMK3RL8)

Drug Name
Somatropin intranasal rhGH
Synonyms
ALTU-238; CP-024; HGH-191; Somatropin (intranasal); Human growth hormone (crystalline), Altus/Genentech; RhGH (oral, eligen), Novartis; Somatropin (crystalline), Altus/Genentech; Somatropin (sustained release, subcutaneous), Althea; Humatrope (oral, CADDYS), Lilly/Emisphere; Recombinant human growth hormone (oral, CADDYS), Lilly/Emisphere; RhGH (oral, CADDYS), Lilly/Emisphere; RhGH (oral, eligen), Emisphere/Novartis; Somatropin (nasal spray, CriticalSorb, growth hormone deficiency), Critical Pharmaceuticals; Somatropin (oral, CADDYS), Lilly/Emisphere; Somatropin (sustained release, subcutaneous), Altus/Genentech; Human growth hormone, (sustained release, subcutaneous), Altus/Genentech
Indication
Disease Entry ICD 11 Status REF
Growth hormone deficiency 5A61.3 Phase 2 [1]
Cross-matching ID
TTD ID
D0C9SW

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Somatotropin (GH1) TTT3YKH SOMA_HUMAN Modulator [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT00837863) Study of Weekly ALTU-238 Compared With Daily Nutropin AQ in Prepubertal Children With Growth Hormone Deficiency. U.S. National Institutes of Health.
2 Long-term efficacy and safety of somatropin for adult growth hormone deficiency.Treat Endocrinol.2003;2(2):109-20.